# Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients

> **NCT02551809** · PHASE2 · COMPLETED · sponsor: **United Neuroscience Ltd.** · enrollment: 43 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **BIOLOGICAL:** UB-311
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02551809
- **Lead sponsor:** United Neuroscience Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2018-08
- **Final completion:** 2018-08
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2020-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02551809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02551809, "Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02551809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*